Levofloxacin Treatment Failure in Haemophilus influenzae Pneumonia

Emerging Infectious Diseases

Volumn 9, Issue 11, 2003, Pages 1475-1478

  Bastida, Teresa ^a   Pérez Vázquez, María ^b   Campos, José ^b   Cortés Lletget, María Cristina ^c   Román, Federico ^b   Tubau, Fe ^c   De la Campa, Adela G ^b   Alonso Tarrés, Carles ^c  

^a HOSPITAL DE L ESPERIT SANT   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

AGED; ARTICLE; BACTERIAL PNEUMONIA; CASE REPORT; CROSS RESISTANCE; FEMALE; GENE MUTATION; HAEMOPHILUS INFLUENZAE; HUMAN; NONHUMAN; TREATMENT FAILURE;

EID: 0242355066     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0911.030176     Document Type: Article

References (15)

1. Ball P, Baquero F, Cars O, File T, Garau J, Klugman K, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002;49:31-40.
2. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
3. Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother 2002;49:709-12.
4. Fenoll A, Jado I, Vicioso D, Pérez A, Casal J. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain (1990 to 1996). J Clin Microbiol 1998;36:3447-54.
5. Campos J, Chanyangam M, deGroot R, Smith AL, Tenover FC, Reig R. Genetic relatedness of antibiotic resistance determinants in multiply resistant Haemophilus influenzae. J Infect Dis 1989;160:810-7.
6. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, Azavedo JCS, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
7. Campos J, Sáez-Nieto JA. Gram negative infections: Haemophilus and other clinically relevant Gram negative coccobacilli. In: Cimolai N, editor. Laboratory diagnosis of bacterial infections. New York: Marcel Dekker, Inc; 2001. p. 557-80.
8. Performance standards for antimicrobial susceptibility testing: eleventh informational supplement. Wayne (PA): National Committee for Clinical Laboratory Standards (NCCLS document no. M100-S11); 2001.
9. Sánchez L, Pan W, Viñas M, Nikaido H. The acrAB homolog of H. influenzae codes for a functional multidrug efflux pump. J Bacteriol 1997;179:6855-7.
10. Campos J, Román F, Georgiou M, García C, Gómez-Lus R, Cantón R, et al. Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. J Infect Dis 1996;174:1345-7.
11. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995;269:496-512.
12. Georgiou M, Muñoz R, Román F, Cantón R, Gómez-Lus R, Campos J, et al. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrob Agents Chemother 1996;40:1741-4.
13. Pérez-Vázquez M, Camacho T, Román F, Campos J, Cantón R. Mutations in quinolone-resistant determining regions (QRDR) of gyrA, gyrB, parC and parE genes in Haemophilus influenzae clinical isolates. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois; December 16-19, 2001; Abstract 145. Washington: American Society for Microbiology; 2001..
14. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001;33(Suppl 3):S147-56.
15. Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997;41:2256-60.